Systematic review and meta-analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn’s disease

Shorter Disease Duration is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease but Not Ulcerative Colitis

(2019) David M. Faleck et al.   Clinical Gastroenterology and Hepatology

Earlier Anti-Tumor Necrosis Factor Therapy of Crohn’s Disease Correlates with Slower Progression of Bowel Damage

(2019) Hinaben Panchal et al.   DIGESTIVE DISEASES AND SCIENCES

Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn’s Disease Studies

(2019) Remo Panaccione et al.   Journal of Crohns & Colitis

P537 The impact of early disease control with vedolizumab on surgery rates among patients with Crohn’s disease: a post-hoc analysis of the GEMINI trials

(2019) P Dulai et al.   Journal of Crohns & Colitis

OP35 Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM

(2019) C Yzet et al.   Journal of Crohns & Colitis

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn’s Disease: Results of the PYRAMID Registry

(2019) Edward V Loftus et al.   INFLAMMATORY BOWEL DISEASES

The Role of Early Biologic Therapy in Inflammatory Bowel Disease

(2019) Dana Rachel Berg et al.   INFLAMMATORY BOWEL DISEASES

ACG Clinical Guideline: Management of Crohn’s Disease in Adults

(2018) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Biologics Delay Progression of Crohn’s Disease, but Not Early Surgery, in Children

(2018) Basavaraj Kerur et al.   Clinical Gastroenterology and Hepatology

Accelerated Step-Up Infliximab Use Is Associated with Sustained Primary Response in Pediatric Crohn’s Disease

(2018) J. Ling et al.   DIGESTIVE DISEASES AND SCIENCES

Secondary Loss of Response to Infliximab in Pediatric Crohn Disease

(2018) Rishi Bolia et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Early Initiation of Tumor Necrosis Factor Antagonist-based Therapy for Patients with Crohn’s Disease Reduces Costs Compared With Late Initiation

(2018) Candace L. Beilman et al.   Clinical Gastroenterology and Hepatology

Can Early Anti-TNF Treatment Modify the Outcome of Inflammatory Strictures?

(2018) Ana Echarri et al.   GASTROENTEROLOGY

Treat-to-target in Crohn’s disease: Will transmural healing become a therapeutic endpoint?

(2018) Elena Daniela Serban   World Journal of Clinical Cases

Top-down approach to biological therapy of Crohn’s disease

(2017) Simon Hirschmann et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Early intervention in Crohn’s disease: towards disease modification trials

(2017) Silvio Danese et al.   GUT

Long-term Outcomes with Anti-TNF Therapy and Accelerated Step-up in the Prospective Pediatric Belgian Crohnʼs Disease Registry (BELCRO)

(2017) Lucas Wauters et al.   INFLAMMATORY BOWEL DISEASES

Crohn's disease

(2017) Joana Torres et al.   LANCET

Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial

(2017) Jean-Frederic Colombel et al.   LANCET

Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study

(2017) Subra Kugathasan et al.   LANCET

Early anti-TNF/immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn’s disease with poor prognostic factors

(2017) Eun Hye Oh et al.   PLoS One

Anti-TNF Therapy Within 2 Years of Crohnʼs Disease Diagnosis Improves Patient Outcomes

(2016) Christopher Ma et al.   INFLAMMATORY BOWEL DISEASES

Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn’s Disease

(2016) Haruhiko Ogata et al.   Journal of Crohns & Colitis

Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease

(2015) E. Safroneeva et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONICpost hocanalysis

(2015) J.-F. Colombel et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Disease Duration Did Not Influence the Rates of Loss of Efficacy of the Anti-TNF Therapy in Latin American Crohn's Disease Patients

(2015) Paulo Gustavo Kotze et al.   DIGESTION

P346. Early treatment with infliximab for Crohn's disease patients

(2015)   Journal of Crohns & Colitis

Prospective Evaluation of the Achievement of Mucosal Healing with Anti-TNF-α Therapy in a Paediatric Crohn’s Disease Cohort

(2015) Federica Nuti et al.   Journal of Crohns & Colitis

Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?

(2015) Veerle Nuij et al.   Journal of Crohns & Colitis

Infliximab “Top-Down” Strategy is Superior to “Step-Up” in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease

(2015) Yoo Min Lee et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial

(2015) Reena Khanna et al.   LANCET

Infliximab Preferentially Induces Clinical Remission and Mucosal Healing in Short Course Crohn’s Disease with Luminal Lesions through Balancing Abnormal Immune Response in Gut Mucosa

(2015) Lijuan Yu et al.   MEDIATORS OF INFLAMMATION

Catching the Therapeutic Window of Opportunity in Early Crohn’s Disease

(2014) Silvio Danese et al.   CURRENT DRUG TARGETS

Can early anti-TNF-α treatment be an effective therapeutic strategy in children with Crohn’s disease?

(2014) Thomas D Walters et al.   Immunotherapy

Infliximab Maintains Durable Response and Facilitates Catch-up Growth in Luminal Pediatric Crohnʼs Disease

(2014) Peter C. Church et al.   INFLAMMATORY BOWEL DISEASES

Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease

(2014) F.M. Ruemmele et al.   Journal of Crohns & Colitis

Early anti-TNF treatment in pediatric Crohn’s disease. Predictors of clinical outcome in a population-based cohort of newly diagnosed patients

(2014) Christine Olbjørn et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Adalimumab Induces Deep Remission in Patients With Crohn's Disease

(2013) Jean–Frédéric Colombel et al.   Clinical Gastroenterology and Hepatology

Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease

(2013) Brian G. Feagan et al.   GASTROENTEROLOGY

Increased Effectiveness of Early Therapy With Anti-Tumor Necrosis Factor-α vs an Immunomodulator in Children With Crohn's Disease

(2013) Thomas D. Walters et al.   GASTROENTEROLOGY

P393 Occurrence of stricturing and penetrating complications is diminished in Crohn's disease patients treated by immunomodulatory and/or anti-TNF therapy within the first two years of disease duration when corrected for diagnostic delay

(2013) E. Safroneeva et al.   Journal of Crohns & Colitis

Response to biologic therapy in Crohnʼs disease is improved with early treatment: An analysis of health claims data

(2012) David T. Rubin et al.   INFLAMMATORY BOWEL DISEASES

Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease

(2012) S. Schreiber et al.   Journal of Crohns & Colitis

Infliximab Therapy Impacts the Peripheral Immune System of Immunomodulator and Corticosteroid Naive Patients with Crohn' Disease

(2011) Kyoichi Kato et al.   Gut and Liver

Infliximab therapy in children with Crohn’s disease: a one-year evaluation of efficacy comparing ‘top-down’ and ‘step-up’ strategies

(2010) Mi Jin Kim et al.   ACTA PAEDIATRICA

Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data

(2010) Stefan Schreiber et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

S1031 Crohn's Disease Mucosal Healing in Adalimumab-Treated Patients is Affected by Disease Duration: Results From Extend

(2010) William J. Sandborn et al.   GASTROENTEROLOGY

Risk Factors Associated With Progression to Intestinal Complications of Crohn's Disease in a Population-Based Cohort

(2010) Kelvin T. Thia et al.   GASTROENTEROLOGY

Top-down therapy for IBD: rationale and requisite evidence

(2010) Geert R. D'Haens   Nature Reviews Gastroenterology & Hepatology

Efficacy of early treatment with infliximab in pediatric Crohn’s disease

(2010) Jong Seung Lee   WORLD JOURNAL OF GASTROENTEROLOGY

S1136 Increased Risk of Clinical Relapse Is Associated with Longer Disease Duration in Crohn's Disease

(2009) David T. Rubin et al.   GASTROENTEROLOGY

Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease

(2009) Filip Baert et al.   GASTROENTEROLOGY

P125 - Influence of disease duration on adalimumab efficacy in Crohn's disease: subanalysis of the CARE trial

(2009) W. Reinisch et al.   Journal of Crohns & Colitis

P192 - Disease duration does not affect outcome following infliximab therapy in children with Crohn's disease

(2009) J. Hyams et al.   Journal of Crohns & Colitis

Initial combination therapy in early Crohn's disease

(2008) William J Sandborn   LANCET

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

(2008) Geert D'Haens et al.   LANCET